Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 ADME Study in Advanced Solid Malignancies
NCT07643870Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd1390 in malignant solid tumor, sponsored by AstraZeneca. Primary endpoints: Mass balance of total radioactivity of AZD1390 and its metabolites at 6 weeks, Pharmacokinetics of AZD1390 at 6 weeks and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
azd1390
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07643870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643870.